Comparison of immediate versus deferred intravitreal Bevacizumab in macular oedema due to branch retinal vein occlusion: a pilot study

Comparison of immediate versus deferred intravitreal Bevacizumab in macular oedema due to branch... Int Ophthalmol (2018) 38:943–949 https://doi.org/10.1007/s10792-017-0538-y ORIGINAL PAPER Comparison of immediate versus deferred intravitreal Bevacizumab in macular oedema due to branch retinal vein occlusion: a pilot study . . M. A. Khan Varakutti Mallika Dattakiran Joshi Received: 6 October 2016 / Accepted: 17 April 2017 / Published online: 21 April 2017 Springer Science+Business Media Dordrecht 2017 Abstract Results The mean visual gain in the two groups early Purpose To compare visual and anatomical recovery and delayed intervention was 0.38 log MARs and 0.15 of immediate versus deferred intravitreal Beva- log MAR units, respectively, and the superior vision cizumab for the treatment of macular oedema sec- gain in the early intervention group was statistically ondary to branch retinal vein occlusion (BRVO). significant (p \ 0.001). The difference in visual Methods In a pilot study, 40 treatment naı¨ve patients improvement between the two groups persisted till of branch retinal vein occlusion with macular oedema 1 year of follow-up. The early intervention group and vision 6/12 or less presenting within one month of required fewer injections (2.6 ± 71 vs. 3.5 ± 0.51), onset were randomised into 2 groups (20 each) to and rescue laser treatment (15 vs. 25%) as compared to receive http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Ophthalmology Springer Journals

Comparison of immediate versus deferred intravitreal Bevacizumab in macular oedema due to branch retinal vein occlusion: a pilot study

Loading next page...
 
/lp/springer_journal/comparison-of-immediate-versus-deferred-intravitreal-bevacizumab-in-8p1Xhk5mlp
Publisher
Springer Netherlands
Copyright
Copyright © 2017 by Springer Science+Business Media Dordrecht
Subject
Medicine & Public Health; Ophthalmology
ISSN
0165-5701
eISSN
1573-2630
D.O.I.
10.1007/s10792-017-0538-y
Publisher site
See Article on Publisher Site

Abstract

Int Ophthalmol (2018) 38:943–949 https://doi.org/10.1007/s10792-017-0538-y ORIGINAL PAPER Comparison of immediate versus deferred intravitreal Bevacizumab in macular oedema due to branch retinal vein occlusion: a pilot study . . M. A. Khan Varakutti Mallika Dattakiran Joshi Received: 6 October 2016 / Accepted: 17 April 2017 / Published online: 21 April 2017 Springer Science+Business Media Dordrecht 2017 Abstract Results The mean visual gain in the two groups early Purpose To compare visual and anatomical recovery and delayed intervention was 0.38 log MARs and 0.15 of immediate versus deferred intravitreal Beva- log MAR units, respectively, and the superior vision cizumab for the treatment of macular oedema sec- gain in the early intervention group was statistically ondary to branch retinal vein occlusion (BRVO). significant (p \ 0.001). The difference in visual Methods In a pilot study, 40 treatment naı¨ve patients improvement between the two groups persisted till of branch retinal vein occlusion with macular oedema 1 year of follow-up. The early intervention group and vision 6/12 or less presenting within one month of required fewer injections (2.6 ± 71 vs. 3.5 ± 0.51), onset were randomised into 2 groups (20 each) to and rescue laser treatment (15 vs. 25%) as compared to receive

Journal

International OphthalmologySpringer Journals

Published: Apr 21, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off